
TG Therapeutics (($TGTX)) has held its Q3 earnings call. Read on for the main highlights of the call. TG Therapeutics delivered a strongly positive earnings call, highlighting record BRIUMVI sales,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TGTX | TG Therapeutics | 63.34 | 33.61 | 113.07% |
| Name | Price | % Change | |
|---|---|---|---|
| $63.34 | +113.07% |

TG Therapeutics (($TGTX)) has held its Q3 earnings call. Read on for the main highlights of the call. TG Therapeutics delivered a strongly positive earnings call, highlighting record BRIUMVI sales,

07:53 EST TG Therapeutics (TGTX) Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More

In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on TG Therapeutics, with a price target of $72.00. Brian Cheng’s rating is based on several

TD Cowen says TG Therapeutics (TGTX)’ Briumvi continues to build toward blockbuster status. The drug’s improving new starts and physician adoption supports higher fiscal 2026 guidance and a greater than

Reports Q3 revenue $259.9M, consensus $245.45M. Michael Weiss, CEO, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global

Cash, cash equivalents and investment securities were $556.7 million as of September 30, 2026. We anticipate that our cash, cash equivalents and investment securities as of September 30, 2026, combined

Raises full year 2026 target BRIUMVI U.S. net product revenue to approximately $915-$920 million; Reaffirms full year 2026 target operating expense guidance, of approximately $450 – $500 million including expenses

TG Therapeutics (TGTX) is scheduled to report 3rd quarter earnings on 11/09/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect TG Therapeutics to post earnings of $0.37

TG Therapeutics ($TGTX) announced an update on their ongoing clinical study. The study, titled “Long-term Follow-up (LTFU) of Study Participants Who Received Azer-Cel,” aims to track safety outcomes for people

TG Therapeutics (TGTX) announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel, an investigational, allogeneic CD19-directed chimeric antigen receptor T-cell therapy, in patients with progressive multiple sclerosis.
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $9.81B | $0.52 | $290.22M | 0.01 | 87.10 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.